Table 2 Possible efficacy in other disorders
Disorder | Author and study type | Anti-CGRP mAb and effect |
|---|---|---|
Episodic Cluster Headache | Goadsby et al. 2019 [123] (RCT) Plato et al. 2021 [125] (RCT) Cited by Carmine Belin et al. 2020 [122] (RCT) | galcanezumab > placebo fremanezumab (trial discontinued for futility) |
Chronic Cluster Headache | Dodick et al. 2020 [126] (RCT) Ruscheweyh et al. 2020 [127], Silvestro et al. 2020 [128] (case series) | galcanezumab = placebo galcanezumab - possibly effective |
Persistent post-traumatic headache | Ashina et al. 2020 [130] (prospective, open label) McVige et al. 2022 [131] (retrospective chart review) Spierings et al. 2023 (abstract) [132] (RCT) | erenumab - marginally effective erenumab, fremanezumab or galcanezumab – possibly effective fremanezumab = placebo |
Vestibular migraine | Hoskin & Fife 2022 [134] (case series) Russo et al. 2023 [135] (prospective, open label) | erenumab, fremanezumab, galcanezumab - probably effective |
Idiopathic intracranial hypertension with persistent headache | Yiangou et al. 2021 [136] (prospective, open label) Frerichs et al. 2022 (abstract) [137] (retrospective chart review)) | erenumab - possibly effective erenumab, fremanezumab, galcanezumab - ineffective |
Trigeminal neuralgia | Parascandolo et al. 2022 [136] (case series) Schott Andersen et al. 2022 (RCT) [137] | erenumab – possibly effective erenumab = placebo |
Mitochondriopathy with chronic migraine with aura | Naegel et al. 2021 [140], Kaltseis et al. 2022 [141] (case reports) | erenumab or galcanezumab - possibly effective |
Nummular headache | Lopez-Bravo et al. 2022 [142] (case report) | galcanezumab - possibly effective |
Neuropathic pain comorbid with chronic migraine | Kang & Govidarajan 2020 [143] (case series) | anti-CGRP mAb not specified – possibly effective |